{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:04:22Z","timestamp":1772118262288,"version":"3.50.1"},"reference-count":35,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2014,10,29]],"date-time":"2014-10-29T00:00:00Z","timestamp":1414540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000001","name":"Alberta Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000521","name":"Canadian Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000521","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2015,3]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Patients with T\u2010cell lymphomas face a poorer prognosis compared with patients with B\u2010cell lymphomas. New therapeutic approaches need to be developed to improve outcomes for these patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>Forty patients with recurrent and refractory T\u2010cell lymphomas other than mycosis fungoides and patients with untreated T\u2010cell lymphoma who were not candidates for combination chemotherapy were prescribed oral lenalidomide at a dose of 25 mg daily on days 1 to 21 of each 28\u2010day cycle, with standardized dose reductions for toxicity. The primary endpoint was overall response rate (ORR), and secondary endpoints were complete and partial response rates, progression\u2010free survival (PFS), overall survival (OS), and safety. The authors also determined duration of response (DoR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>A total of 40 patients were enrolled in the current study; 1 patient was subsequently deemed ineligible. The ORR was 10 of 39 patients (26%); 3 patients (8%) achieved complete responses and 7 patients achieved partial responses. Three patients had stable disease for \u22655 cycles. The median OS was 12 months (range &lt;1 month to \u226569 months), the median PFS was 4 months (range, &lt;1 month to \u226550 months), and the median DoR was 13 months (range 2 months to \u226537 months), including 5 responses that lasted &gt;1 year. Toxicity was in keeping with the known safety profile of lenalidomide. Among the patients who had recurrent\/refractory peripheral T\u2010cell lymphoma (29 patients), the ORR was 24%, the median OS was 12 months, the median PFS was 4 months, and the median DoR was 5 months (range, 2 months to \u226537 months).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>\n                      In the current study, the use of oral lenalidomide monotherapy demonstrated clinically relevant efficacy among patients with systemic T\u2010cell lymphomas. It appears to have excellent potential as an agent in combination therapy for patients with T\u2010cell lymphoma.\n                      <jats:bold>\n                        <jats:italic>Cancer<\/jats:italic>\n                        2015;121:716\u2013723.\n                      <\/jats:bold>\n                      \u00a9\n                      <jats:italic>2014 American Cancer Society<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.29103","type":"journal-article","created":{"date-parts":[[2014,10,29]],"date-time":"2014-10-29T13:02:03Z","timestamp":1414587723000},"page":"716-723","source":"Crossref","is-referenced-by-count":90,"title":["Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T\u2010cell lymphoma"],"prefix":"10.1002","volume":"121","author":[{"given":"Ethan","family":"Toumishey","sequence":"first","affiliation":[{"name":"Department of Medicine Dalhousie University Saint John New Brunswick Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angeli","family":"Prasad","sequence":"additional","affiliation":[{"name":"Department of Oncology University of Alberta Edmonton Alberta Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greg","family":"Dueck","sequence":"additional","affiliation":[{"name":"Medical Oncology British Columbia Cancer Agency, Centre for the Southern Interior Kelowna British Columbia Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Chua","sequence":"additional","affiliation":[{"name":"Department of Oncology University of Alberta Edmonton Alberta Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daygen","family":"Finch","sequence":"additional","affiliation":[{"name":"Medical Oncology British Columbia Cancer Agency, Centre for the Southern Interior Kelowna British Columbia Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Johnston","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Manitoba Winnipeg Manitoba Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"van der Jagt","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Ottawa Ottawa Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doug","family":"Stewart","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Calgary Calgary Alberta Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darrell","family":"White","sequence":"additional","affiliation":[{"name":"Department of Medicine Dalhousie University Halifax Nova Scotia Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Belch","sequence":"additional","affiliation":[{"name":"Department of Oncology University of Alberta Edmonton Alberta Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony","family":"Reiman","sequence":"additional","affiliation":[{"name":"Department of Medicine Dalhousie University Saint John New Brunswick Canada"},{"name":"Canadian Cancer Society Research Chair University of New Brunswick Fredericton New Brunswick Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,10,29]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25377"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.3883"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.7524"},{"key":"e_1_2_7_5_1","first-page":"10","article-title":"Peripheral T\u2010cell lymphomas: progress and challenges","volume":"11","author":"Savage KJ","year":"2012","journal-title":"Oncology Exchange"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428191003721342"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.8133"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.04.029"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.573031"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq626"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12008"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.163.1.380"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.10.4914"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-217687"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06841.x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0512-7"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mvr.2005.01.002"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1244917"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1244851"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4223"},{"key":"e_1_2_7_22_1","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1182\/blood.V110.11.3453.3453","article-title":"Belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T\u2010cell lymphoma: results of a phase II study","volume":"110","author":"Advani R","year":"2007","journal-title":"Blood"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.9024"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06457.x"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-542142"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.7285"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.8793"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12678"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2009-0"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.728597"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2014.01.011"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.3647"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.10.1298"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.3429"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-268862"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.29103","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.29103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T16:18:14Z","timestamp":1760285894000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.29103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,29]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["10.1002\/cncr.29103"],"URL":"https:\/\/doi.org\/10.1002\/cncr.29103","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725089388.793539752","asserted-by":"object"}]},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,29]]}}}